Fosrenol

Lanthanum Carbonate tablets, indicated for the treatment of kidney failure and would facilitate phosphate absorption, are currently sold under the 'Fosrenol' brand by its innovator Shire Plc. Natco had filed an abbreviated new drug application (ANDA) seeking the US Food and Drug Administration's (USFDA) approval for marketing generic versions of Fosrenol in 500mg, 750mg and 1gm dosages.

Top Stories - Google News 2009

Lanthanum Carbonate tablets, indicated for the treatment of kidney failure and would facilitate phosphate absorption, are currently sold under the 'Fosrenol' brand by its innovator Shire Plc. Natco had filed an abbreviated new drug application (ANDA) seeking the US Food and Drug Administration's (USFDA) approval for marketing generic versions of Fosrenol in 500mg, 750mg and 1gm dosages.

unknown title 2009

Keryx management is aiming specifically to take market share from Genzyme but also believes Zerenex has competitive advantages over smaller players including PhosLo and Fosrenol.

Keryx Pharmaceuticals Rallies but Remains Undervalued -- Seeking Alpha 2010

Zerenex may offer safety advantages to existing phosphate binders such as Phoslo and Fosrenol while offering much less frequent dosing compared to Renagel/Renvela, in addition to the absence of GI/bloating side effects.

SeekingAlpha.com: Home Page 2010

Zerenex represents a niche market opportunity within well understood/established class of drugs (phosphate binders) that has a key differentiation of being iron-based compared to existing treatments such as PhosLo, Fosrenol, and Renagel/Renvela.

SeekingAlpha.com: Home Page 2010

And although an increase in the use of calcium based phosphate binders was deemed to be "not in the best interest of the patient" by a majority of medical directors, future market share projections indicate increased use of these agents in place of more expensive, non-calcium agents such as Genzyme's Renagel/Renvela and Shire's Fosrenol.

Medindia Health News 2010

Shire slipped 7p to 812. 5p as it filed a lawsuit against US group Mylan claiming a patent infringement on its Fosrenol kidney drug.

Blogposts | guardian.co.uk 2009

Thursday alleging that Natco, in an effort to sell a generic version of Shire's Fosrenol drug, violated two Shire patents.

National Business News - Local Business News | bizjournals 2009

Fosrenol is prescribed for patients with chronic kidney disease who suffer from hyperphosphatemia, an electrolyte disturbance that causes an abnormally high level of phosphate in their blood.

National Business News - Local Business News | bizjournals 2009

BRIEF-Shire files lawsuit against Mylan for infringement of Fosrenol patent -

Forbes.com: News 2009